Nucleus Genomics CEO explains how “genetic optimization” tools help parents select traits they desire in babies

The field of genetics has seen significant advancements in recent years, sparking a controversial debate on whether parents should have the ability to design their unborn children. Kian Sadeghi, a 25-year-old entrepreneur and CEO of Nucleus Genomics, firmly believes in what he calls “genetic optimization,” allowing parents to select desired traits for their future offspring, ranging from physical attributes like height and weight to intelligence levels.

Inspired by a personal tragedy involving a cousin with a rare genetic illness, Sadeghi founded Nucleus Genomics in 2021, with the support of influential investors such as Peter Thiel and Alexis Ohanian. The company offers a program called IVF+ for $30,000, which includes comprehensive DNA screening of both parents and up to 20 embryos conceived through in vitro fertilization. The results are presented in a user-friendly format, allowing parents to make informed decisions about the genetic makeup of their future child.

Nucleus Genomics conducts advanced DNA screenings for over 2,000 traits and conditions, including eye and hair color, intelligence, and even predisposition to medical conditions like depression and autism. While proponents argue that this technology can prevent disease and create healthier offspring, critics raise concerns about the ethical implications of manipulating genetic traits, drawing comparisons to the controversial concept of eugenics.

Sadeghi defends his company’s approach, emphasizing that the goal is to empower parents with information to give their children the best start in life. He acknowledges that parents may seek specific traits like height or IQ, but he believes that DNA is not the sole determinant of a person’s destiny. Factors like upbringing, education, and serendipity play a significant role in shaping an individual’s life.

Despite the growing popularity of companies like Nucleus Genomics, medical experts warn about the ethical dilemmas surrounding reproductive genetics. The American College of Medical Genetics and Genomics has expressed concerns about the rapid advancement of genetic screening technologies without sufficient evidence or consideration of broader ethical and regulatory issues.

While Sadeghi remains confident in the accuracy of Nucleus Genomics’ predictors, he emphasizes that DNA is just one piece of the puzzle in determining a person’s traits and capabilities. He rejects the notion that his company is creating a new class of “superhumans,” emphasizing the importance of environmental factors and personal choices in shaping an individual’s life trajectory.

As the debate over genetic optimization and designer babies continues to evolve, it raises important questions about the intersection of science, ethics, and personal choice in shaping the future of human reproduction.